Takeda’s Entyvio Defends Share Against Janssen’s Stelara in the Crohn’s Disease Market, and Pressure in the Ulcerative Colitis Market May Heat Up in Early 2018 if Pfizer’s Xeljanz Secures an FDA Win
According to a new report by Spherix Global Insights, Janssen’s Remicade is taking a dual hit from the expansion of alternative mechanism of action biologics such as Entyvio and Stelara as well as the slow, but growing, adoption of infliximab biosimilars in the IBD market Download Report Overview EXTON, Pa. Nov. 21, 2017 /PRNewswire/ — […]
Recent Chart Audit Reveals Switching Rheumatoid Arthritis Patients to Roche/Genentech’s RoActemra (Actemra) is Significantly More Common in the EU5 than it is in the US
EU5 adoption of Pfizer’s Xeljanz and Eli Lilly’s Olumiant has been largely limited to rheumatologists practicing in Germany, according to a recently released independent report by Spherix Global Insights Download Report Overview EXTON, Pa., Nov. 21, 2017 /PRNewswire/ — Analysis of over 2,200 RA patients in the US and EU5 (France, Germany, Italy, Spain, and […]
Early Adopters in Germany and the United Kingdom Are Prescribing Merck KGaA’s Mavenclad as First-Line Induction Therapy for the Treatment of Multiple Sclerosis
European neurologists predict substantial uptake of Roche’s Ocrevus among primary progressive multiple sclerosis patients driven by favorable market access status and an absence of on-label competition, according to a new EU5 report from Spherix Global Insights Download Report Overview EXTON, Pa., Nov. 21, 2017 /PRNewswire/ — The multiple sclerosis (MS) market in the EU is […]
Cardiologists Continue to Lag Nephrologists When It Comes to the Adoption of Vifor/Relypsa’s Veltassa for Hyperkalemia, but Prescribers in Both Specialties Report Mounting Market Access Pressure
At nearly two years post launch, close to 90% of nephrologists are using Veltassa compared to 61% of cardiologists and promotion could be a major factor in the difference between the specialties according to the latest quarterly update from Spherix Global Insights Download Report Overview (Cardiology) Download Report Overview (Nephrology) EXTON, Pa., Nov. 16, 2017 […]
Cosentyx Plateaus as Non-TNF Agents Prepare to Dominate in Psoriatic Arthritis
From: Specialty Pharma Time By: Lauren Santye Although there are a growing number of rheumatologists in the United States who report the use of Cosentyx to treat psoriatic arthritis (PsA), the increasing user base has failed to translate into overall increases in biologic share, according to market research company Spherix Global Insights. The plateau of […]
Novartis’ Cosentyx Beginning to Plateau in Psoriatic Arthritis, as US Rheumatologists Prepare for an Influx of Non-TNF Agents, Such as BMS’ Orencia, Pfizer’s Xeljanz, and Lilly’s IL-17, Taltz
Despite an increasing user base, Cosentyx share has remained unchanged over the past six months, according to recently released data from Spherix Global Insights Download Report Overview EXTON, Pa., Aug. 15, 2017 /PRNewswire/ — In the most recent quarterly update of RealTime Dynamix™ Psoriatic Arthritis, a growing population of US rheumatologists (n=101) are reporting use […]
RealTime Dynamix™: Crohn’s Disease US Q2
Crohn’s Disease (CD) is a common form of inflammatory bowel diseases, currently affecting the lives of approximately 700,000 Americans. Theintroduction of biologics has changed the face of treatment for moderateto-severe CD patients. However, recent launches, an active pipeline, and the imminent introduction of biosimilars present an opportunity for major future shifts in the CD landscape. […]
RealTime Dynamix™: Hyperkalemia (Neph) US Q2
The hyperkalemia market underwent sweeping changes with the introduction of Relypsa’s Veltassa in the beginning of 2016. Veltassa represented the first new therapy for the treatment of hyperkalemia in over 50 years. In 2017, a new competitor in AstraZeneca/ZS Pharma’s ZS-9 may come into play after being delayed by a Complete Response Letter in 2016. […]
RealTime Dynamix™: Rheumatoid Arthritis US Q2
The US biologics and small molecule market for the treatment of rheumatoid arthritis (RA) is well established with a variety of drugs and mechanisms of action for treatment. Though the backbone TNF-inhibiting biologics have dominated the space for nearly two decades, more recent launches, an active pipeline, and the imminent introduction of biosimilars present an […]
RealTime Dynamix™: Bone and Mineral US Q2
The management of hyperphosphatemia, secondary hyperparathyroidism and vitamin D deficiency are challenging conditions to manage in dialysis patients. These conditions are also highly prevalent in later-stage CKD-ND patients.Current therapeutic options have multiple limitations and are associated with poor adherence. Recent launches of iron-based, non-calcium phosphate binders have not measurably shifted the market. This monthly report […]
